What is MapLight Therapeutics, Inc. 's stock-based comp?

MapLight Therapeutics, Inc. (MPLT) reported stock-based comp of $9.64M in Q1 2026.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

MapLight Therapeutics, Inc. MPLT Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

Johnson & JohnsonJNJ

$300M+4.2%

Neurocrine BiosciencesNBIX

$57.2M+8.3%

Acadia PharmaceuticalsACAD

$14.7M+29.2%

AbbVieABBV

$444M+8.3%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$2.57M+305%

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+100%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's stock-based comp?: MapLight Therapeutics, Inc. (MPLT) reported stock-based comp of $9.64M in Q1 2026.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.